THORNE HEALTHTECH SHARES RESULTS OF COLLABORATIVE CLINICAL TRIAL WITH MAYO CLINIC AND HEALTHTECH CONNEX, INC. - "THE EFFECTS OF A DIETARY SUPPLEMENT ON BRAIN FUNCTION AND STRUCTURE IN JUNIOR A ICE HOCKEY PLAYERS"
On April 4, 2023, Thorne HealthTech (NASDAQ: THRN) announced significant findings from a double-blinded, placebo-controlled trial measuring brain function in 30 Junior A ice hockey players. Conducted in collaboration with Mayo Clinic and HealthTech Connex, the study aimed to evaluate the effects of Thorne's SynaQuell® supplement on brain function during a hockey season. Key results showed positive changes in selective attention, visual processing speed, and neurofilament light levels, indicating potential benefits for athletes, particularly those with concussion histories. The full results are expected later this year.
- Significant positive changes in brainwave latency and visual processing speed for participants using SynaQuell compared to placebo.
- Notable improvements in neurofilament light levels and processing of stimuli in participants with concussions.
- First evidence supporting SynaQuell's role in enhancing brain health for athletes.
- None.
Significant positive findings from a double-blinded, placebo-controlled trial that measured brain function in ice hockey players over a season
The double-blinded, placebo-controlled trial measured the brain function of 30 ice hockey players over the course of their season. The trial was led by
The following are the study's findings:
- For all participants – those with and without a history of prior concussions – there were significant positive changes in the following when comparing the SynaQuell group to the placebo group:
- Brainwave latency specific selective attention and focus (N100)
- Visual processing speed tests
- For all participants, there were trend differences when comparing the SynaQuell group to the placebo group in the following areas:
- Neurofilament Light (NfL) levels, which assesses neuronal damage from sports-related impacts
- Processing of stimuli, which includes visual and auditory words, pictures, and gestures (N400)
- In participants who had a history of concussions there were additional significant positive changes when comparing the SynaQuell group to the placebo group:
- Neurofilament Light (NfL) levels, which assesses neuronal damage from sports-related impacts
- Processing of stimuli, which includes visual and auditory words, pictures, and gestures (N400)
- For all participants, the SynaQuell group showed notable improvement over the placebo group in these important measures of brain function and brain processing speed
"This is the first evidence of its kind to showcase the use of SynaQuell as a nutrient blend for supporting brain health in athletes engaged in a contact sport," said
"We believe this is the first study around nutritional support that highlights a demonstrative improvement of critical measures of brain function and structure over the period of a contact sport season where repetitive head impacts occurred," said Dr.
The full study and results are expected to be available later this year. For more details on the recently completed and ongoing clinical trials related to the effect of SynaQuell on brain function being conducted at the
About
View original content to download multimedia:https://www.prnewswire.com/news-releases/thorne-healthtech-shares-results-of-collaborative-clinical-trial-with-mayo-clinic-and-healthtech-connex-inc--the-effects-of-a-dietary-supplement-on-brain-function-and-structure-in-junior-a-ice-hockey-players-301790060.html
SOURCE
FAQ
What were the main findings of the THRN clinical trial announced on April 4, 2023?
How many players participated in Thorne HealthTech's trial?
What is the purpose of the SynaQuell supplement in the study?
When can we expect the full results of the Thorne trial?